Home > Gastroenterology > UEGW 2019 > Inflammatory Bowel Diseases > First evidence of long-term efficacy of ABX464 in ulcerative colitis

First evidence of long-term efficacy of ABX464 in ulcerative colitis

Expert
Prof. Severine Vermeire, University Hospital Leuven, Belgium
Conference
UEGW 2019

Prof. Severine Vermeire (University Hospital Leuven, Belgium) presented a 1-year, open-label ABX464 maintenance study conducted in 22 ulcerative colitis (UC) patients without treatment interruption after completion of the randomised, double-blind, placebo-controlled 8 weeks induction study [1]. A total of 19 patients completed the 1-year maintenance study and showed good long-term safety and tolerability of 50 mg given orally over 52 weeks.

ABX464 is an oral drug candidate for UC, among other chronic inflammation disorders, with a novel mechanism of action based on the upregulation of a single microRNA (miRNA-124) with anti-inflammatory properties.

At month 12, an endoscopy to assess clinical remission status (the critical parameter for regulatory authorities) was performed in 16/19 UC patients. During treatment with ABX464, patients reduced their mean total Mayo Score from 8.7 to 1.9 (-78%), their endoscopic subscore from 2.3 to 0.25 (-89%), and th...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on